ObjectiveTo summarize the research progress on cell cycle dysregulation in pancreatic ductal adenocarcinoma (PDAC), to explore its roles in PDAC development, malignant biological behavior, and therapeutic resistance, and to provide references for the optimization of cell cycle-related targeted therapeutic strategies. MethodsRelevant studies published in recent years on the role of cell cycle dysregulation in the development of PDAC were systematically retrieved and reviewed. ResultsCell cycle dysregulation is involved in multiple stages of PDAC development and progression, promoting sustained tumor cell proliferation, therapeutic resistance, and malignant progression. Therapeutic strategies targeting key cell cycle regulators, including CDK4/6, ATR, CHK1, and WEE1, have shown promising potential. However, the efficacy of monotherapy remains limited, and further optimization of combination strategies and patient selection is still needed. ConclusionsCell cycle dysregulation is an important biological basis for PDAC development and therapeutic resistance, and it also represents a potential therapeutic entry point. Further clarification of its molecular mechanisms and optimization of biologically guided combination strategies may provide new directions for improving PDAC treatment.